Index RUT
P/E -
EPS (ttm) -0.74
Insider Own 1.51%
Shs Outstand 192.74M
Perf Week -6.17%
Market Cap 186.26M
Forward P/E -
EPS next Y -1.05
Insider Trans -1.21%
Shs Float 189.83M
Perf Month 5.91%
Income -91.17M
PEG -
EPS next Q -0.43
Inst Own 55.12%
Short Float 16.78%
Perf Quarter -33.81%
Sales 21.73M
P/S 8.57
EPS this Y 11.53%
Inst Trans 7.50%
Short Ratio 4.00
Perf Half Y -74.50%
Book/sh 2.08
P/B 0.46
EPS next Y 32.83%
ROA -16.08%
Short Interest 31.86M
Perf Year -73.23%
Cash/sh 0.95
P/C 1.02
EPS next 5Y 45.80%
ROE -47.81%
52W Range 0.85 - 5.53
Perf YTD -29.97%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -20.06%
52W High -82.52%
Beta 0.84
Dividend TTM -
Quick Ratio 1.42
Sales past 5Y 120.04%
Gross Margin -15.86%
52W Low 13.56%
ATR (14) 0.09
Dividend Ex-Date -
Current Ratio 1.55
EPS Y/Y TTM 87.79%
Oper. Margin -1523.91%
RSI (14) 42.87
Volatility 5.82% 9.06%
Employees -
Debt/Eq 1.36
Sales Y/Y TTM 322.60%
Profit Margin -419.62%
Recom 2.79
Target Price 3.89
Option/Short Yes / Yes
LT Debt/Eq 1.04
EPS Q/Q 29.93%
Payout -
Rel Volume 0.41
Prev Close 0.97
Sales Surprise -3.44%
EPS Surprise -6.05%
Sales Q/Q 17353.52%
Earnings May 09 BMO
Avg Volume 7.96M
Price 0.97
SMA20 -2.53%
SMA50 -12.99%
SMA200 -55.87%
Trades
Volume 3,289,825
Change -0.29%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-11-23 Downgrade
HSBC Securities
Hold → Reduce
Dec-08-23 Upgrade
Morgan Stanley
Underweight → Equal-Weight
$3 → $7
Oct-17-23 Initiated
Cantor Fitzgerald
Neutral
Sep-06-23 Initiated
HSBC Securities
Buy
$4.21
Jul-19-23 Upgrade
BofA Securities
Neutral → Buy
$6 → $10
Jun-01-23 Upgrade
Barclays
Equal Weight → Overweight
$7 → $8
Apr-28-23 Initiated
JP Morgan
Overweight
$7
Mar-07-23 Initiated
Robert W. Baird
Outperform
$10
Aug-05-22 Upgrade
Barclays
Underweight → Equal Weight
Aug-02-22 Upgrade
Raymond James
Mkt Perform → Outperform
$8
Apr-06-22 Downgrade
Cowen
Outperform → Market Perform
Mar-07-22 Downgrade
Barclays
Equal Weight → Underweight
$4
Nov-08-21 Reiterated
Wells Fargo
Equal Weight
$25 → $16
Nov-08-21 Reiterated
Wedbush
Neutral
$22 → $11
Nov-08-21 Reiterated
RBC Capital Mkts
Sector Perform
$26 → $14
Nov-08-21 Reiterated
Canaccord Genuity
Hold
$20 → $15
Nov-08-21 Reiterated
Barclays
Equal Weight
$20 → $13
Nov-08-21 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$11
Nov-08-21 Downgrade
Goldman
Neutral → Sell
$23 → $10
Aug-10-21 Resumed
William Blair
Mkt Perform
Show Previous Ratings
May-17-24 03:46PM
May-16-24 09:22AM
May-14-24 11:24AM
May-10-24 03:36PM
01:34PM
07:00AM
Loading…
May-09-24 07:00AM
May-07-24 12:40PM
May-06-24 07:05AM
07:00AM
Apr-26-24 04:43PM
04:05PM
Apr-16-24 02:05PM
Apr-15-24 08:15AM
Apr-13-24 04:22PM
Apr-11-24 08:30AM
08:00AM
Loading…
08:00AM
Apr-02-24 11:33AM
Mar-29-24 05:20AM
Mar-27-24 11:37AM
10:00AM
Mar-26-24 07:01AM
Mar-25-24 04:05PM
Mar-19-24 07:44AM
Mar-18-24 06:05PM
08:00AM
Mar-13-24 07:50AM
Mar-11-24 08:00AM
Mar-05-24 06:56PM
Jan-27-24 07:28AM
05:27AM
06:55AM
Loading…
Jan-10-24 06:55AM
Jan-08-24 08:00AM
Jan-04-24 03:32PM
(The Wall Street Journal) +5.84%
Jan-03-24 07:15AM
Jan-02-24 08:00AM
Dec-26-23 08:00AM
Dec-24-23 07:39AM
Dec-23-23 07:30AM
Dec-22-23 08:45AM
Dec-20-23 02:23PM
01:54PM
Dec-19-23 09:41PM
Dec-18-23 04:01PM
Dec-15-23 11:14AM
Dec-11-23 05:43AM
Dec-10-23 12:02PM
Dec-09-23 11:31AM
Dec-08-23 01:45PM
(The Wall Street Journal) -40.54%
01:01PM
12:35PM
Dec-07-23 11:30AM
08:45AM
Dec-01-23 07:41AM
Nov-29-23 02:28PM
Nov-26-23 04:44PM
Nov-24-23 07:00AM
(The Wall Street Journal)
Nov-08-23 03:39PM
Nov-07-23 05:18PM
08:00AM
07:46AM
07:27AM
(Associated Press Finance)
07:00AM
Nov-04-23 08:45AM
Nov-02-23 09:37AM
Oct-30-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 09:47AM
Sep-29-23 09:00AM
Sep-20-23 07:21AM
Sep-12-23 07:00AM
05:14AM
Sep-07-23 11:30AM
Sep-05-23 04:05PM
Aug-29-23 05:25AM
Aug-28-23 08:30AM
Aug-24-23 10:15AM
Aug-16-23 07:00AM
Aug-08-23 08:25AM
07:18AM
07:00AM
07:00AM
Aug-05-23 09:40AM
Jul-27-23 11:19AM
Jul-25-23 08:00AM
Jul-22-23 06:14AM
Jul-20-23 01:14AM
Jul-19-23 12:36PM
Jun-30-23 10:15AM
Jun-29-23 09:53AM
07:45AM
Jun-21-23 07:00AM
Jun-15-23 10:00AM
Jun-08-23 11:30AM
Jun-01-23 02:09AM
May-10-23 07:57AM
May-09-23 07:10AM
07:00AM
Apr-27-23 04:05PM
Apr-24-23 03:49PM
07:30AM
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Obenshain Andrew President and CEO Mar 04 '24 Sale 1.53 6,095 9,311 279,998 Mar 05 05:40 PM Klima Thomas J See Remarks Mar 04 '24 Sale 1.53 4,573 6,986 124,840 Mar 05 05:39 PM Colvin Richard A Chief Medical Officer Mar 01 '24 Sale 1.53 6,770 10,342 118,368 Mar 05 05:40 PM Vittiglio Joseph Chief Business & Legal Officer Feb 05 '24 Sale 0.90 5,217 4,708 44,783 Feb 06 04:07 PM Klima Thomas J See Remarks Feb 05 '24 Sale 0.90 2,714 2,449 129,413 Feb 06 04:07 PM Obenshain Andrew President and CEO Feb 05 '24 Sale 0.90 1,879 1,696 286,093 Feb 06 04:07 PM Obenshain Andrew President and CEO Jan 05 '24 Sale 1.43 3,162 4,520 287,972 Jan 09 04:05 PM Colvin Richard A Chief Medical Officer Jan 05 '24 Sale 1.42 597 845 125,138 Jan 09 04:05 PM Krawtschuk Christopher Chief Financial Officer Dec 06 '23 Sale 4.52 4,526 20,437 45,474 Dec 08 04:42 PM Obenshain Andrew President and CEO Nov 03 '23 Sale 3.17 807 2,555 291,134 Nov 03 04:10 PM Colvin Richard A Chief Medical Officer Nov 02 '23 Sale 2.98 2,343 6,975 125,735 Nov 03 04:10 PM Klima Thomas J See Remarks Sep 05 '23 Sale 3.79 922 3,493 132,127 Sep 06 04:30 PM Obenshain Andrew President and CEO Aug 10 '23 Sale 3.54 16,929 59,956 291,941 Aug 10 05:00 PM Klima Thomas J See Remarks Jun 02 '23 Sale 3.50 4,130 14,451 133,049 Jun 06 04:06 PM
Index -
P/E -
EPS (ttm) -10.14
Insider Own 57.82%
Shs Outstand 1.61M
Perf Week -7.22%
Market Cap 2.90M
Forward P/E -
EPS next Y -
Insider Trans -1.03%
Shs Float 0.68M
Perf Month -19.64%
Income -16.28M
PEG -
EPS next Q -
Inst Own 8.51%
Short Float 3.87%
Perf Quarter -29.12%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans 111.80%
Short Ratio 0.46
Perf Half Y -52.63%
Book/sh 11.86
P/B 0.15
EPS next Y -
ROA -25.22%
Short Interest 0.03M
Perf Year -78.98%
Cash/sh 12.89
P/C 0.14
EPS next 5Y 41.70%
ROE -62.64%
52W Range 1.86 - 16.74
Perf YTD -50.14%
Dividend Est. -
P/FCF -
EPS past 5Y -37.86%
ROI -34.95%
52W High -89.25%
Beta 0.45
Dividend TTM -
Quick Ratio 6.05
Sales past 5Y -16.71%
Gross Margin -1320.56%
52W Low -3.23%
ATR (14) 0.31
Dividend Ex-Date -
Current Ratio 6.05
EPS Y/Y TTM 89.49%
Oper. Margin 0.00%
RSI (14) 40.37
Volatility 23.62% 12.91%
Employees 1
Debt/Eq 1.55
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 10.00
Option/Short No / Yes
LT Debt/Eq 1.45
EPS Q/Q 93.95%
Payout -
Rel Volume 10.82
Prev Close 1.98
Sales Surprise -
EPS Surprise -1377.78%
Sales Q/Q -100.00%
Earnings -
Avg Volume 57.81K
Price 1.80
SMA20 -16.24%
SMA50 -23.59%
SMA200 -51.46%
Trades
Volume 625,449
Change -9.09%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-09-22 Initiated
H.C. Wainwright
Buy
$17
Apr-13-21 Initiated
Jefferies
Buy
$29
Apr-13-21 Initiated
Evercore ISI
Outperform
$34
Apr-13-21 Initiated
BofA Securities
Buy
$25
May-13-24 10:54AM
Mar-25-24 09:52PM
Nov-22-23 09:14AM
Jun-09-23 07:00AM
May-11-23 05:05AM
(American City Business Journals) -5.06%
07:00AM
Loading…
May-10-23 07:00AM
Apr-25-23 04:05PM
Apr-18-23 04:01PM
Mar-25-23 09:34AM
Mar-23-23 04:05PM
Jan-24-23 01:53PM
(American City Business Journals)
10:55AM
08:00AM
Nov-10-22 08:15AM
07:00AM
08:00AM
Loading…
Nov-09-22 08:00AM
Oct-24-22 08:00AM
Sep-05-22 12:00PM
Sep-01-22 02:23PM
(American City Business Journals)
08:00AM
05:32AM
(American City Business Journals)
Aug-26-22 07:37AM
Aug-25-22 04:30PM
Aug-11-22 07:00AM
Aug-10-22 08:06AM
Jul-20-22 09:48AM
Jun-02-22 07:00AM
May-17-22 08:00AM
May-16-22 07:00AM
May-09-22 08:22AM
12:10PM
Loading…
Apr-29-22 12:10PM
Apr-28-22 05:20PM
Apr-20-22 12:33PM
Apr-19-22 02:08PM
(American City Business Journals)
08:30AM
Mar-31-22 04:56PM
Mar-19-22 08:04AM
Mar-01-22 04:30PM
Feb-23-22 07:00AM
Feb-10-22 07:00AM
Jan-18-22 05:38PM
Jan-06-22 07:00AM
Jan-04-22 07:00AM
Dec-23-21 04:38AM
(Simply Wall St.) +15.77%
Dec-20-21 07:00AM
Dec-17-21 06:31AM
Nov-11-21 07:00AM
Nov-10-21 07:15AM
07:05AM
07:00AM
Nov-09-21 04:30PM
Oct-25-21 07:00AM
Oct-18-21 08:58AM
Oct-12-21 07:00AM
Oct-05-21 07:00AM
Sep-08-21 07:00AM
Sep-07-21 07:00AM
Aug-18-21 08:54AM
Aug-10-21 03:54PM
07:05AM
07:00AM
Jun-28-21 07:00AM
May-28-21 07:00AM
May-13-21 07:00AM
May-06-21 07:00AM
Apr-27-21 07:00AM
Mar-19-21 04:25PM
Mar-18-21 10:32PM
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SMISEK JEFFERY A Director Mar 28 '24 Sale 2.57 6,642 17,070 0 Mar 29 04:15 PM SMISEK JEFFERY A Director Mar 28 '24 Sale 2.61 1,600 4,176 6,512 Mar 29 04:15 PM SMISEK JEFFERY A Director Nov 22 '23 Sale 3.64 1,470 5,351 6,642 Nov 27 04:54 PM Graf Susan E Director Jun 09 '23 Buy 0.27 5,010 1,353 5,010 Jun 09 04:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite